# Spironolactone in Atrial Fibrillation

Study · id `cardio:ct-nct02673463` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02673463](<https://clinicaltrials.gov/study/NCT02673463>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02673463

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 250 participants.

## Technical summary

Registry record NCT02673463. Randomized; quadruple masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2018-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 250 participants (planned count; ClinicalTrials.gov record NCT02673463, source copy `cardio:ctgov-nct02673463-2018-10-11`, retrieved 2026-10-26)
- Start date: 2015-01 (registry gives no type) (ClinicalTrials.gov record NCT02673463, source copy `cardio:ctgov-nct02673463-2018-10-11`, retrieved 2026-10-26)
- Primary completion: 2018-12 (anticipated) (ClinicalTrials.gov record NCT02673463, source copy `cardio:ctgov-nct02673463-2018-10-11`, retrieved 2026-10-26)
- Completion: 2019-03 (anticipated) (ClinicalTrials.gov record NCT02673463, source copy `cardio:ctgov-nct02673463-2018-10-11`, retrieved 2026-10-26)
- Countries: United Kingdom (ClinicalTrials.gov record NCT02673463, source copy `cardio:ctgov-nct02673463-2018-10-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02673463-2018-10-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Spironolactone in Atrial Fibrillation
- Acronym: IMPRESS-AF
- Condition: Atrial Fibrillation
- Intervention (Drug): Spironolactone
- Intervention (Drug): Placebo
- Lead sponsor: University of Birmingham
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: University of Birmingham (`cardio:org-university-of-birmingham`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS-AF Trial (`cardio:pubmed-32909497`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 57dc43a2911fa982481a3143e3d61f46727fc2eefdb2ca0e89cc31dc0a3ccfe8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
